Earnings summaries and quarterly performance for X4 Pharmaceuticals.
Executive leadership at X4 Pharmaceuticals.
Board of directors at X4 Pharmaceuticals.
Research analysts who have asked questions during X4 Pharmaceuticals earnings calls.
ET
Edward Tenthoff
Piper Sandler Companies
4 questions for XFOR
Also covers: ARVN, ARWR, CAPR +14 more
SW
Stephen Willey
Stifel Financial Corp.
4 questions for XFOR
Also covers: ABCL, CELC, CGEN +10 more
DB
David Bautz
Zacks Small Cap Research
3 questions for XFOR
Also covers: ARMP, AURX, BCLI +1 more
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
3 questions for XFOR
Also covers: ABSI, BSEM, CGEN +24 more
Kristen Kluska
Cantor Fitzgerald
2 questions for XFOR
Also covers: ABEO, ADMA, AQST +24 more
Ayan Hussein
Cantor Fitzgerald
1 question for XFOR
Also covers: RIGL
DM
Douglas Macpherson
Mizuho Securities
1 question for XFOR
Also covers: ALEC, QSI
LR
Leah Rush Cann
Brookline Capital Markets, LLC
1 question for XFOR
Also covers: SYRS
Recent press releases and 8-K filings for XFOR.
X4 Pharmaceuticals Provides Update on Mavorixafor Development and Financial Position
XFOR
Management Change
New Projects/Investments
Guidance Update
- X4 Pharmaceuticals (XFOR) has a new management team, including Executive Chair Adam Craig, who joined approximately three months ago.
- The company recently raised just under $240 million in cash, which is sufficient to complete the Phase 3 trial for mavorixafor in chronic neutropenia and fund the company through to launch.
- The lead compound, mavorixafor, is FDA-approved for WHIM syndrome but is being developed for the broader chronic neutropenia indication, estimated to affect 15,000 patients.
- The Phase 3 FORWARD study for chronic neutropenia is currently just over one-third enrolled. Enrollment is projected to conclude by the end of Q3 2026, with top-line data expected in the second half of 2027, aiming for a launch in 2028.
Nov 10, 2025, 1:30 PM
X4 Pharmaceuticals Discusses Mavorixafor Development for Chronic Neutropenia and Clinical Trial Progress
XFOR
Management Change
New Projects/Investments
Guidance Update
- Adam Craig, Executive Chair, and a new management team recently joined X4 Pharmaceuticals, raising just under $240 million in cash to fund the Phase III trial for mavorixafor in chronic neutropenia through to launch.
- The company's lead compound, mavorixafor, is already FDA-approved for WHIM syndrome but is commercially focused on the broader chronic neutropenia indication, which targets an estimated 15,000 patients.
- The Phase III 4WARD Study for chronic neutropenia is just over one-third enrolled. Enrollment is expected to finish by the end of Q3 2026, with top-line data anticipated in the second half of 2027, and a potential launch in 2028.
- Mavorixafor is an oral agent that releases neutrophils from the bone marrow, offering a competitive advantage over current injectable treatments like G-CSF.
Nov 10, 2025, 1:30 PM
X4 Pharmaceuticals Secures Funding and Accelerates Phase 3 Trial for Mavorixafor in Chronic Neutropenia
XFOR
New Projects/Investments
Guidance Update
Management Change
- X4 Pharmaceuticals has secured just under $240 million in cash, providing sufficient funding to complete the Phase 3 trial for mavorixafor in chronic neutropenia and support a potential launch in 2028.
- The company's sole focus is the Phase 3 "forward" study of mavorixafor for chronic neutropenia, a condition affecting an estimated 15,000 patients.
- Enrollment for the Phase 3 study is just over one-third complete, with top-line data anticipated in the second half of 2027 and a potential launch in 2028.
- Mavorixafor, an oral agent, is expected to offer a competitive advantage over current injectable treatments like G-CSF for chronic neutropenia.
Nov 10, 2025, 1:30 PM
X4 Pharmaceuticals Reports Q3 2025 Results, Announces Strategic Restructuring and Extended Cash Runway
XFOR
Earnings
Layoffs
Guidance Update
- X4 Pharmaceuticals reported a net loss of $29.8 million, or $0.69 per share, on $1.765 million in total revenue for the third quarter ended September 30, 2025.
- The company successfully completed two financial transactions, raising $240.3 million in gross proceeds, which is expected to extend its cash runway to the end of 2028.
- X4 Pharmaceuticals has undergone a corporate restructuring, including a 50% workforce reduction expected to generate $13 million in annualized cost savings, and has shifted its primary focus to the advancement of the 4WARD Phase 3 chronic neutropenia trial.
Nov 5, 2025, 1:05 PM
X4 Pharmaceuticals Announces Closing of Public Offering
XFOR
- X4 Pharmaceuticals announced the closing of its previously announced underwritten public offering on October 27, 2025.
- The offering included 52,844,000 shares of common stock at a public offering price of $2.90 per share and 700,000 pre-funded warrants at $2.899 per pre-funded warrant.
- The aggregate gross proceeds to X4 from the offering were approximately $155.3 million.
- After giving effect to the offering, the total shares outstanding for X4 Pharmaceuticals are 79,214,708.
Oct 27, 2025, 11:05 PM
X4 Pharmaceuticals, Inc. Announces Public Offering of Common Stock and Warrants
XFOR
- X4 Pharmaceuticals, Inc. entered into an underwriting agreement on October 23, 2025, to sell 45,860,000 shares of common stock at $2.90 per share and pre-funded warrants to purchase 700,000 shares at $2.899 per share.
- The underwriters fully exercised their option on October 24, 2025, to purchase an additional 6,984,000 shares of common stock.
- The company expects to receive approximately $145.6 million in net proceeds from the offering, which is anticipated to close on October 27, 2025.
Oct 24, 2025, 10:47 PM
X4 Pharmaceuticals Prices $135 Million Public Offering
XFOR
New Projects/Investments
- X4 Pharmaceuticals (XFOR) announced the pricing of an underwritten public offering of 45,860,000 shares of common stock at $2.90 per share and pre-funded warrants to purchase up to 700,000 shares at $2.899 per pre-funded warrant.
- The offering is expected to generate approximately $135 million in aggregate gross proceeds before deductions and is anticipated to close on October 27, 2025.
- The net proceeds from this offering will be used to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as for general and administrative expenses, capital expenditures, working capital, and other general corporate purposes.
- The underwriters have been granted a 30-day option to purchase up to an additional 6,984,000 shares of common stock.
Oct 24, 2025, 4:37 AM
X4 Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
XFOR
Layoffs
Management Change
Guidance Update
- X4 Pharmaceuticals announced a strategic restructuring on September 17, 2025, which includes a 50% reduction in its workforce.
- This initiative is anticipated to generate annualized cost savings of approximately $13 million.
- The company estimates it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs, with the workforce reduction substantially completed in the third quarter of 2025.
- As part of the restructuring, John Volpone was appointed Chief Operating Officer in addition to his role as President, while the former Chief Operating Officer, Chief Commercial Officer, Chief Legal & Compliance Officer, and Chief Medical Officer are exiting the company.
Sep 17, 2025, 11:03 AM
Quarterly earnings call transcripts for X4 Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more